Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Small-Cell Lung Cancer.

Oberotatug ravtansine is under clinical development by Oxford BioTherapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.

This is part of the government’s broader effort to improve healthcare accessibility and support patients in need, according ...

The union government has reduced GST on three cancer drugs from 12% to 5%, following an earlier exemption from basic customs ...

Treatment of non-small cell lung cancer (NSCLC) depends on the stage you're in and can include chemotherapy, surgery, ...

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of lung cancer cases. The treatment plan and goal of treatment depend on the stage of your ...

Dr. Debu Tripathy, editor-in-chief of CURE magazine, discusses the advancements made in small cell lung cancer.

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses ... high-grade T1 urothelial cancer of the ...

Bladder cancer hopes back on track There was better ... after a new FDA approval in non-small cell lung cancer (NSCLC). In the age of AI, large data sets – like the treasure trove of customer ...